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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe branchiomeric skeletal muscles co-evolved with new chambers of the heart to enable predatory feeding in chordates. These co-
evolved tissues develop from a common population in anterior splanchnic mesoderm, referred to as cardiopharyngeal mesoderm
(CPM). The regulation and development of CPM are poorly understood. We describe an embryonic stem cell-based system in which
MESP1 drives a PDGFRA+ population with dual cardiac and skeletal muscle differentiation potential, and gene expression resembling
CPM. Using this system, we investigate the regulation of these bipotent progenitors, and find that cardiac specification is governed by
an antagonistic TGFb-BMP axis, while skeletal muscle specification is enhanced by Rho kinase inhibition. We define transcriptional sig-
natures of the first committed CPM-derived cardiac and skeletal myogenic progenitors, and discover surface markers to distinguish car-
diac (PODXL+) from the skeletal muscle (CDH4+) CPM derivatives. These tools open an accessible window on this developmentally and
evolutionarily important population.INTRODUCTION
Cardiac and skeletal myogenesis both generate striated
muscle, but are traditionally thought of as two separate
processes with distinct developmental anlagen. However,
recent work suggests the existence of at least one bipotent
anlage for cardiac and skeletal muscle: the common pro-
genitor population that leads to the formation of both
the head muscles and the second heart field (Lescroart
et al., 2010; Nathan et al., 2008; Tirosh-Finkel et al.,
2006), and which is unique to chordates (Diogo et al.,
2015). Somite-derived myogenesis depends on PAX3 to
initiate the core myogenic network (Tajbakhsh et al.,
1997), but the head muscles do not derive from a PAX3+
progenitor, instead requiring TBX1 and PITX2 (Sambasivan
et al., 2009). These genetic differences between head
and trunk muscles may have functional consequences,
as several muscular dystrophies have differential severity
in craniofacial skeletal muscles compared with trunk
muscles (e.g., facioscapulohumeral muscular dystrophy
shows greater involvement of facial muscles, while
Duchenne muscular dystrophy shows less). Cranial myo-
genesis has been much less investigated than somite-
derived myogenesis.
Cranial mesoderm can be divided into three regions: pre-
chordal mesoderm, cranial paraxial mesoderm, and cardio-26 Stem Cell Reports j Vol. 6 j 26–34 j January 12, 2016 j ª2016 The Authorpharyngeal mesoderm (CPM). CPM, also known as lateral
splanchnic mesoderm, is the only embryonic population
with both cardiac and skeletal myogenic potential, giving
rise to second heart field and distal facial skeletal muscles
(e.g., digastric, mylohyoid, and stylohyoid) (Lescroart
et al., 2010; Tirosh-Finkel et al., 2006). This developmental
intimacymayexplainwhy cardiac and craniofacial congen-
ital defects are often linked,withDiGeorge syndrome being
a prominent example (Hutson and Kirby, 2003).
The transcription factor MESP1 is essential to mesoderm
patterning (Saga et al., 1999). In the ascidianCiona, cells ex-
pressing the homolog Mesp give rise to the trunk ventral
cells, which subsequently develop into cardiac and skeletal
progenitors (Satou et al., 2004). The Ciona trunk ventral
cells thus act as the ascidian CPM (Razy-Krajka et al.,
2014). In the mouse, MESP1 is the earliest acting factor in
heart development (Saga et al., 1999).We recently reported
that MESP1 also promotes other mesoderm lineages
including hematopoietic and skeletal myogenic (Chan
et al., 2013). Lineage-tracing studies further revealed that
Mesp1+ cells contribute to the muscle stem cell pool of the
head (Chanet al., 2013;Harel et al., 2009).While the cardiac
effects ofMESP1 arewell studied (Bondue et al., 2008, 2011;
David et al., 2008; Lindsley et al., 2008), the mechanisms
governing the differentiation of theseMesp1-marked bipo-
tent CPM progenitors remain poorly understood.s
Figure 1. MESP1 Promotes Cardiac or Skeletal Myogenic Differentiation Depending on Serum-Factor Signaling
(A) MESP1 induced a KDR PDGFRA+ population in day-5 EBs cultured in serum-free condition.
(B) These putative paraxial mesoderm cells gradually acquired a skeletal myogenic fate that was tubular, MYOGENIN+, a-actinin+, and
myosin heavy chain (MHC)+ by day 12 (top row). Serum supplement from day 5 produced cardiac cells that were planar, MYOGENIN,
a-actinin+, and MHC+ (bottom row). Images are representative of five independent experiments. Scale bar represents 100 mm.
(C) Scheme depicting the protocol used to evaluate the effects of various treatments on MESP1-induced cardiac versus skeletal myogenic
differentiation.
(D) Quantitative RT-PCR analysis showing that the addition of serum downregulated skeletal myogenic genes (Tcf15, Myf5, Myod1, Myog)
and upregulated cardiac genes (Isl1, Nkx2-5, Gata4, Tbx5, Tnnt2) as early as 24 hr (left), and also after 7 days (right) (n = 12, from four
independent experiments). Mean ± SEM is shown.
See also Figure S1 and Tables S1 and S2.Here we report that under serum-free conditions, MESP1
induction in embryonic stem (ES) cells produces PDGFRA+
progenitors with dual cardiac/skeletal myogenic potential,
functionally resembling CPM. We further demonstrate the
robustness of this MESP1-induced system for identifying
pathways that enhance the cardiac/skeletal myogenic
bifurcation and discovering cell-surface proteins asmarkers
to distinguish these two lineages.RESULTS AND DISCUSSION
MESP1 Induces Cardiac or Skeletal Myogenic
Differentiation Depending on Serum-Factor Signaling
We have previously developed a mouse ES cell line in
which MESP1 expression can be tightly regulated by the
addition of doxycycline (Dox) (Chan et al., 2013). In
embryoid bodies (EBs) cultured in serum-free medium,
mesoderm does not form, as evidenced by the absence ofStemKDR (Flk-1) and PDGFRA (PDGFRa) (Figure 1A, No Dox).
In contrast, MESP1 induction from days 3–5 of serum-free
culture generated a KDR PDGFRA+ population (Figure 1A,
Dox). When attached and continued in serum-free culture,
skeletalmyocytes emerged by day 12 (Figure 1B, top row). If
serum was included from the start, MESP1 induction led to
cardiac differentiation instead (Chan et al., 2013). We next
performed differentiation in serum-free conditions, but
added back serum at day 5. Surprisingly, this converted dif-
ferentiation toward cardiac instead of skeletal myogenic
(Figure 1B, bottom row). We tested different windows of
MESP1 induction to map the window of maximal skeletal
myogenic activity and found that the day 3–8 window
was optimal (Figure S1A); thus this window was used for
subsequent studies (Figure 1C).
Gene expression analysis revealed that within 24 hr of
serum addition, paraxial mesoderm (Tcf15, paraxis) and
skeletal myogenic genes (Myf5) were downregulated while
cardiac genes (Isl1, Nkx2-5, and Gata4) were upregulatedCell Reports j Vol. 6 j 26–34 j January 12, 2016 j ª2016 The Authors 27
Figure 2. MESP1-Induced PDGFRA+ Pro-
genitors Give Rise to Cardiac or Skeletal
Myogenic Derivatives at a Single-Cell
Level
(A) Paraxial mesoderm genes (Meox1, Tcf15)
and CPM genes (Tbx1, Pitx2, Ebf1, Lhx2)
were enriched in MESP1-induced day-5
PDGFRA+ cells cultured in serum-free con-
dition (n = 6, from two independent exper-
iments). Mean ± SEM is shown.
(B) Immunostaining shows that day-5
PDGFRA+ cells predominantly acquire a
skeletal myogenic fate (MHC+ MYOGENIN+)
in serum-free conditions or a cardiac fate
(MHC+ MYOGENIN) in serum-containing
condition by day 12, but PDGFRA cells do
not acquire either fate. Images are repre-
sentative of three independent experiments.
Scale bar represents 100 mm.
(C) Quantitative RT-PCR shows that the
default skeletal myogenic differentiation of
day-5 PDGFRA+ cells under serum-free con-
ditions switches to cardiac in the presence
of serum (n = 6, from two independent ex-
periments). Mean ± SEM is shown.
(D and E) Clonal analysis of MESP1-induced
PDGFRA+ cells. (D) Single EGFP-labeled
MESP1-induced PDGFRA+ cells gave rise to
cardiac (CM) or skeletal myogenic (SKM)
derivatives. Images are representative of
four independent experiments. (E) A single
MESP1-induced PDGFRA+ cell differentiated
into both cardiac (arrowhead) and skeletal
myogenic (arrow) lineages. Cells were grown
in serum-free conditions supplemented
with Y27632, conditions under which skel-
etal myogenic differentiation predominates.
Scale bar represents 50 mm.
(F) Sarcomeric structures were observed in cardiac (left) and skeletal myogenic derivatives (right). Areas depicted by the white dotted
rectangle are magnified for clarity. Scale bar represents 20 mm.
See also Figure S2 and Tables S1 and S2.(Figure 1D, left panel). Further culture to day 12 potenti-
ated these effects, with enhanced Tnnt2 (cardiac troponin
T) and reduced Myod1 (MyoD) and Myog (myogenin)
expression (Figure 1D, right panel). We also tested serum
add-back over different windows and found add-back
from day 5 to be the most potent (Figure S1B). Therefore,
both cardiac and skeletal myogenic progenitors derive
from a common MESP1+ population, and the cardiac line-
age choice can be driven by factors present in serum.
MESP1-Induced PDGFRA+ Cells Functionally
Resemble CPM at the Single-Cell Level
We next addressed whether specification of these two line-
ages is pre-determined prior to, or occurs after, MESP128 Stem Cell Reports j Vol. 6 j 26–34 j January 12, 2016 j ª2016 The Authorinduction. A clear positive answer could be obtained if a
single cell were found to give rise to progeny of both cardiac
and skeletal myogenic cells. We first confirmed that the
PDGFRA+ fraction was enriched for paraxial mesoderm
genes such as Meox1 and Tcf15 (Figure 2A). Importantly,
transcription factors pertaining to CPM, including Tbx1,
Pitx2, Ebf1, and Lhx2, were indeed enriched in PDGFRA+
cells (Figure 2A). Upon further culture in serum-containing
or serum-free conditions, PDGFRA+ cells differentiated
into cardiac or skeletal myogenic derivatives, respectively,
but PDGFRA cells did not (Figures 2B and 2C).
Single PDGFRA+ cells had poor survival upon fluores-
cence-activated cell sorting (FACS) and rarely produced col-
onies, but cloning efficiency was increased by culture on as
Figure 3. Signaling Environment Governs Cardiac versus Skeletal Myogenic Differentiation of MESP1+ Mesoderm
(A) Screening of modulators of signaling pathways involved in myogenesis revealed that BMP4 decreased skeletal myogenic gene
expression and increased cardiac gene expression by day 12 (n = 3, technical replicates).
(B) BMP4 promoted cardiac at the expense of skeletal myogenic differentiation as early as 24 hr (left) and after 7 days (right) (n = 3,
technical replicates).
(C) Immunostaining using pan-troponin I (for both skeletal and cardiac) and cardiac-specific troponin I verified that MESP1 induced pan-
TnI+ cTnI skeletal myogenic cells in serum-free conditions (control), whereas BMP4 produced pan-TnI+ cTnI+ cardiac cells instead.
(D and E) ALK4/5/7 inhibition by A83-01 promoted cardiac differentiation, as shown by immunostaining (D) and quantitative RT-PCR (E)
(n = 3, technical replicates). Efficiency of differentiation was determined by staining for MHC and DAPI, and analyzing images with G-Tool
(Ippolito et al., 2012) (n = 3). Images are representative of three independent experiments.
(F) TGFb/activin-BMP antagonism, as shown by TGFb1 and activin A diminishing the pro-cardiac effect of BMP4 (n = 3, technical
replicates).
(legend continued on next page)
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mouse embryonic fibroblast (MEF) feeder layer. To distin-
guish MESP1-induced PDGFRA+ cells from MEFs, we engi-
neered an EGFP-labeled MESP1-inducible ES cell line (Fig-
ures S2A–S2C). Although most cells committed to one or
the other fate (Figure 2D), we observed that cardiac and
skeletal myogenic progenitors were occasionally found
within the same colony (Figure 2E, arrowhead and arrow,
respectively), demonstrating that a single PDGFRA+ cell
had the potential to give rise to both lineages.
MESP1-Induced CPM Cardiac Derivatives Have
Second Heart Field Characteristics
We further evaluated the maturity of MESP1-induced
CPM derivatives. Using optimal pro-cardiac or pro-skeletal
myogenic culture conditions, CPM derivatives with
clear sarcomeric structures were readily observed (Fig-
ure 2F). The maturity of CPM cardiac derivatives was
also confirmed by observation of spontaneous rhythmic
contractions (Movie S1).
We next compared the cardiac differentiation efficiency
of the current CPM protocol with the previously reported
MESP1-induced serum-throughout protocol (Chan et al.,
2013). Whereas a simple serum add-back regimen was
suboptimal in promoting cardiac differentiation, supple-
mental ALK4/5/7 inhibition (by A83-01, see below) in
PDGFRA+-sorted cells greatly induced the expression of
cardiac genes comparable with the serum-throughout pro-
tocol (Figure S2D). The CPM protocol thus efficiently gen-
erates cardiac progenitors.
During development, cardiac progenitors derived from
CPM constitute the second heart field which populates
both atria. Indeed, MESP1-induced CPM cardiac deriva-
tives predominantly expressed atrial specific genes,
including transcription factor (Nr2f2, COUP-TFII), myosin
(Myl2, Mlc-2a), ion channel (Kcnj3, Kir3.1) and secretory
peptide (Nppa, ANP) (Figure S2E). Conversely, ventricular
specific genes such as Hand1 and Myl2 (Mlc-2v) were en-
riched in cardiac progenitors produced using the conven-
tional protocol (Chan et al., 2013) (Figure S2F).
A Subset of BMPs Promotes Cardiac at the Expense of
Skeletal Myogenic Differentiation of MESP1+
Mesoderm
CPM is marked byMesp1 lineage tracing (Saga et al., 1999)
and is known to be regulated by bone morphogenetic pro-
tein (BMP) signaling (Tzahor et al., 2003). To gain insight
into signaling pathways that may regulate the cardiac(G and H) ROCK inhibition by Y27632 promoted skeletal myogenic dif
PCR (H) (n = 3, technical replicates). Efficiency of skeletal myogeni
Images are representative of three independent experiments.
(I) Y27632 improved the survival of MESP1-induced PDGFRA+ cells by
Mean ± SEM is shown in (A), (B), and (D)–(H). Scale bar represents 100
30 Stem Cell Reports j Vol. 6 j 26–34 j January 12, 2016 j ª2016 The Authorversus skeletal myogenic switch in this in vitro system,
and to determine its relevance to CPM, we screened a panel
of growth factors with known contributions to cardiac or
skeletal myogenesis during embryo development. Among
them, BMP4 downregulated skeletal myogenic genes and
upregulated cardiac genes by day 12 (Figure 3A). This bias
was apparent as early as 24 hr and was sustained for
7 days (Figures 3B and 3C). Thus, like CPM, which line-
age-traces to Mesp1+ founders, the ES cell-derived MESP1-
induced PDGFRA+ population responds to BMP4 signaling
by selecting the cardiac fate over the skeletalmyogenic fate.
As BMP4 belongs to the transforming growth factor b
(TGFb) superfamily, we next investigated the activities of
the entire family (Figure S3A). BMP2, which is highly
related to BMP4, behaved similarly, and BMP9 and 10
were somewhat effective. Interestingly, several other BMP
members inhibited skeletal myogenesis but had minimal
pro-cardiac response. Factors from branches outside of
the BMP subfamily, including TGFb1/2/3, activin A, and
nodal, did not promote cardiac specification.
Inhibition of ALK4/5/7 and ROCK Improves
Generation of MESP1+ Mesoderm Derivatives
To gain further insight into the cardiac-skeletalmuscle line-
age decision, we screened 80 inhibitors of defined stem
cell-related signaling pathways for the ability to modulate
differentiation of MESP1-induced day-5 PDGFRA+ cells
(Table S3). Under serum-replete conditions, we found
that SB431542, A83-01, GW788388, and RepSox further
enhanced cardiac differentiation (Figures 3D and S3B).
Notably, these all suppress the TGFb/activin/nodal sig-
naling pathway by inhibiting ALK4/5/7 (TGFb type I recep-
tors), and, as exemplified by A83-01, expression of cardio-
genic genes was upregulated (Figure 3E). As TGFb1/2/3,
activin A, and nodal by themselves provide no bias toward
cardiac or skeletal myogenesis (Figure S3A), we speculate a
probable TGFb1/activin A-BMP4 pathway antagonism
(Candia et al., 1997) in which the pro-cardiac effect of
ALK4/5/7 inhibition might be due to a potentiation of
BMP4 signaling. Indeed, BMP4-mediated cardiac gene up-
regulation was reduced by TGFb1 and more profoundly
so by activin A (Figure 3F).
We also found five compounds that further enhanced
skeletal myogenic differentiation in the serum-free con-
dition: Y27632, SR3677, GSK429286, thiazovivin (all
Rho-associated kinase [ROCK] inhibitors), and blebbistatin
(inhibitor of myosin II ATPase, a downstream target offerentiation, as shown by immunostaining (G) and quantitative RT-
c differentiation was determined, as above, using G-Tool (n = 3).
inhibiting apoptosis (Annexin V+ 7-AAD+/).
mm in (C), (D), and (G). See also Figure S3 and Tables S1, S2, and S3.
s
ROCK signaling [Somlyo and Somlyo, 2000]) (Figures 3G
and S3C). Y27632 was further shown to upregulate the
expression of Myod1 and Myog (Figure 3H). Moreover,
similar to the protective role of ROCK inhibition for the
survival of human pluripotent cells (Watanabe et al.,
2007), Y28732 improved the survival of PDGFRA+-sorted
cells cultured in serum-free conditions by inhibiting
apoptosis (Figure 3I). In serum-containing (pro-cardiac)
conditions, very few cells experienced apoptosis and
Y27632 did not enhance the expression of cardiac genes
(Figures S3D and S3E).
PODXL and CDH4 Distinguish MESP1-Induced Early
Cardiac and Skeletal Myogenic-Committed Cells,
Respectively
The clear bifurcation between cardiac and skeletal
myogenic differentiation and our ability to manipulate
this CPM-like population by addition of cytokines makes
it a powerful system for discovering early-acting factors
within each lineage. We therefore performed RNA seq-
uencing (RNA-seq) on four different CPM-derived popula-
tions: early cardiac (day 6, BMP4-treated for 24 hr), late
cardiac (day 12, BMP4-treated for 7 days), early skeletal
myogenic (day 6, untreated) and late skeletal myogenic
(day 12, untreated) (Figures 4A, S4A, and S4B).
We reasoned that factors distinguishing cardiac versus
skeletal myogenesis would be discovered at the earliest
stage (i.e., day 6), and evaluated these genes for a mem-
brane protein subset (Figures 4B and 4C). We further inter-
rogated this list by antibody screening to identify potential
early lineage-specific markers. We found that PODXL (po-
docalyxin) marked a portion of BMP4-treated cells (Fig-
ure 4D, left column). PODXL+ cells were enriched for
cardiac transcripts (Figure 4E, left two panels), and gener-
ated cardiac progenitors abundantly (Figure 4F, left panel).
On the other hand, CDH4 (cadherin-4) labeled the major-
ity of untreated cells, and its expression was substantially
reduced by BMP4 (Figure 4D, right column). Skeletal
myogenic gene expression was enriched in the CDH4+
population (Figure 4E, right two panels), and skeletal
myogenic progenitors could only be generated from
these cells (Figure 4F, right panel). Interestingly, Podxl and
Cdh4 expression were downregulated in PODXL+- and
CDH4+-sorted populations over time (Figure S4C), suggest-
ing that both markers transiently label progenitors. In a
conventional serum-throughout protocol, cardiac genes
were also primarily expressed in the PODXL+ fraction
(Figure S4D). Our results therefore identify PODXL and
CDH4 as surface markers to distinguish the earliest CPM-
derived cardiac and skeletal myogenic-committed cells,
respectively.
CPM is the only embryonic population with dual car-
diac/skeletal myogenic potential, and little is known aboutStemits regulation. There are somemajor obstacles hindering its
study in an in vivo or ex vivo setting: the embryo at this
early stage of development is very small, CPM is morpho-
logically indistinguishable from other head mesoderm
domains (Tzahor, 2015), and currently there is no known
specific marker for its prospective isolation. An in vitro
model of this bipotent tissue is of significant value in
addressing these problems.
Under serum-free conditions in which ES cells do not
differentiate into mesoderm, MESP1 is sufficient to drive
mesoderm differentiation (Chan et al., 2013). We show
here that this serum-free MESP1-induced mesoderm com-
prises a PDGFRA+ progenitor population that functionally
resembles the CPM, i.e., these cells can further differentiate
into either cardiac or skeletal myogenic cells, or in some
cases both simultaneously.
In Vitro MESP1-Induced Mesoderm Allows
Investigation of the Bifurcation of Early Cardiac and
Skeletal Myogenic Progenitors
Using our in vitro CPM-modeling system, we have identi-
fied signaling pathways that enhanced cardiac or skeletal
myogenic differentiation.We show that cardiac versus skel-
etal myogenesis of CPM is governed by signaling through
an antagonistic TGFb1/activin A-BMP2/4 axis, i.e., cardio-
genesis is driven by both inhibition of TGFb1/activin A
signaling and stimulation of BMP2/4 signaling. TGFb-BMP
antagonism has been demonstrated in the differentiation
of other musculoskeletal lineages, including bone (Spine-
lla-Jaegle et al., 2001) and cartilage (Keller et al., 2011).
Since the developing cranial anlage is surrounded with
TGFb and BMP signaling modulators (Bothe et al., 2011),
this antagonistic TGFb-BMP axis is likely relevant to the
fates of other head mesoderm-derived lineages. We have
also demonstrated that skeletal myogenesis is sensitive to
Rho kinase signaling. These data validate the in vitromodel
for determining pathways involved in cardiac and skeletal
myogenic differentiation.
The use of lineage-specific surface markers is fundamen-
tally essential to distinguish and prospectively isolate line-
age-primed/committed cells. KDR and PDGFRA have been
extensively utilized to identify lateral plate mesoderm
(leading to blood) and paraxial mesoderm (leading to
trunk/limb skeletal muscles), respectively (Sakurai et al.,
2006). Selection of the cardiac versus skeletal myogenic
fate is rarely studied (Magli et al., 2014), and currently there
are no surface markers to distinguish these two lineages
from their common progenitor pool. Using the current
in vitro system, we have identified and subsequently vali-
dated PODXL and CDH4 as surface markers for early
CPM-derived lineage-restricted derivative progenitors.
PODXLwas recently reported tomarkearlyhematopoietic
progenitors from another bipotent mesodermal progenitorCell Reports j Vol. 6 j 26–34 j January 12, 2016 j ª2016 The Authors 31
Figure 4. PODXL and CDH4 Distinguish MESP1-Induced Early Cardiac and Skeletal Myogenic Progenitors, Respectively
(A) Principal-component analysis of RNA-seq data generated from early (day 6) versus late (day 12) cardiac (CM) versus skeletal myogenic
(SKM) populations (n = 3 independent experiments).
(B and C) RNA-seq analysis of early cardiac versus skeletal myogenic populations revealed a total of 669 genes whose expression was
significantly altered during the early fate-specification process (B), wherein existed a membrane proteins subset (C).
(D) PODXL (podocalyxin) marked a portion of early cardiac progenitors (left column), and CDH4 (cadherin-4) marked most early skeletal
myogenic progenitors (right column). FACS analysis was performed on MESP1-induced day-6 early cardiac (BMP4-treated, top row) and
skeletal myogenic (untreated, bottom row) cells.
(E) PODXL+ sorted cells were highly enriched for cardiac transcripts (left two panels), and similarly, skeletal myogenic transcripts were
abundantly found in CDH4+ sorted cells (right two panels) (n = 3, technical replicates). Mean ± SEM is shown.
(F) Immunostaining of day-12 cells previously sorted on day 6 based on PODXL and CDH4 expression. In BMP4-treated cells, cardiac
progenitors were enriched in the PODXL+ fraction (left); whereas in untreated cells, skeletal myogenic progenitors were only observed in
the CDH4+ fraction (right). Images are representative of three independent experiments. Scale bar represents 100 mm.
See also Figure S4 and Tables S1 and S2.cell, the hemangioblast (Zhang et al., 2014). Interestingly,
early cardiogenic genes were enriched in both the KDR+
PODXL+ and KDR+ PODXL populations. Surprisingly, in
that study efficient cardiac differentiationwasonlyobserved
from PODXL cells. This later resultmay be due to the tran-
sient nature of podocalyxin expression, but may also reflect32 Stem Cell Reports j Vol. 6 j 26–34 j January 12, 2016 j ª2016 The Authordifferences between the two sequential waves of cardiac
development, i.e., first heart field cells (previous report)
and second heart field cells (current study).
The current study demonstrates the development of
bipotent PDGFRA+ cardiac/skeletal myogenic progeni-
tors from MESP1+ mesoderm, which molecularly ands
functionally mimics the CPM of early embryogenesis.
As such, this in vitro system represents a tractable model
in which to study this developmentally important
population.EXPERIMENTAL PROCEDURES
The CPM differentiation protocol is illustrated in Figure 1C. RNA-
seq datasets can be accessed on GEO: GSE74682. Details of the
following are included in the Supplemental Experimental Proce-
dures: generation of MESP1-inducible ES cells, cell culture and dif-
ferentiation, clonal analysis of single cells, gene expression and
RNA-seq analysis, immunostaining, flow cytometry and apoptosis
analysis, and chemical screening.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, three tables, and one movie and can be
found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2015.12.003.
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